The Ireland Kidney Function Test
Market is expected to grow at an impressive rate during the forecast period due
to the rising kidney or renal dysfunction, increasing investments by market
players, rising R&D activities, high prevalence of kidney diseases, rising
government initiatives, and technological innovations. These factors are
expected to significantly drive the growth of the Ireland Kidney Function Test
market.
Additionally, the rise in
healthcare initiatives and schemes is expected to bolster the growth of the
Ireland Kidney Function Test Market in the forecast period 2024-2028. For
instance, Nova Biomedical introduced a novel tool with advanced technology in
March 2022 to promote kidney treatment by early diagnosis of the illness and
renal function testing in 'Point-of-care testing (POCT)' settings outside of
the hospital. The company's technology has been validated in clinical studies
conducted in a variety of non-hospital settings, including community health
centers, pharmacies, imaging facilities, doctor's offices, clinics, and
individual home testing.
A kidney function test refers to a
series of medical tests and diagnostic procedures such as the Blood Urea
Nitrogen (BUN) Test, Serum Creatinine Test, Glomerular Filtration Rate (GFR)
Calculation, and Kidney Biopsy, etc. These tests are performed to assess the
health and functionality of the kidneys and provide valuable information about
their ability to filter waste products, regulate fluid and electrolyte balance,
and produce hormones necessary for maintaining overall health.
The growing prevalence of acute
kidney injury (AKI) and associated chronic kidney disease (CKD) is projected to
drive the kidney function tests market during the forecast years. Chronic
kidney diseases refer to persistent renal function and structural deformities
that have been present for a minimum of 3 months. Lifestyle diseases and kidney
injuries are significant risk factors for kidney diseases and are the foremost
cause of illness and death across Ireland. According to an article published in
'Our health service' journal, Chronic Kidney Disease (CKD) affects 1 in 10
people. Often described as 'a silent illness hiding in plain sight', it usually
develops slowly over time and can progress to total kidney failure. It is estimated
that CKD will become the fifth leading cause of death globally by 2040. Over
500 new patients in Ireland develop kidney failure every year. Early diagnosis
of chronic kidney disease (CKD) through screening is key to better health
outcomes while easing the burden on our health service. The Irish Kidney
Association (IKA), in association with the HSE's National Renal Office (NRO),
is running an awareness campaign to highlight the importance of early screening
for chronic kidney disease (CKD). This, in turn, is expected to propel the
growth of the Ireland Kidney Function Test market.
Furthermore, the increased
adoption of digital urinalysis indicates the growing demand for home
diagnostics, which is driving the growth of the Ireland Kidney Function Test
Market. Several companies are developing FDA-cleared at-home smartphone
urinalysis tests to help people seeking kidney tests for proteins. The
company's urinalysis test uses disposable cups and strips in combination with a
smartphone camera to interpret and read results prominently.
Rising Prevalence of Chronic
Kidney Diseases:
The increasing prevalence of
kidney diseases, such as chronic kidney disease (CKD), diabetic nephropathy,
and renal infections, is a major driving force behind the kidney function test
market. As the incidence of these conditions rises, the demand for diagnostic
tests to assess kidney function and detect diseases early also increases, thus
boosting the growth of the Ireland Kidney Function Test Market. According to a
research paper published in an article, the prevalence of CKD in the health
system was 11.8%, 10.9% in men, and 12.6% in women. This corresponds to a
detection rate of 4.5% (5.1% in women and 3.9% in men). The prevalence of CKD
was significantly higher in women than in men (12.6% versus 10.9%, P <
0.001), older age groups, and patients with a history of Acute Kidney Injury
(AKI). Therefore, the prevalence of CKD in the Irish health system is 11.8%,
corresponding to a detection rate of 4.5% in the general population.
Demographic and geographic factors, as well as acute kidney injury episodes, are
important determinants of chronic kidney disease compared to other diseases.
Thus, this factor is expected to bolster the growth of the Ireland Kidney
Function Test Market.
Increasing Prevalence of Diabetes
and Hypertension
Diabetes and hypertension are two
leading causes of kidney disease. Individuals with diabetes are at risk of
developing diabetic nephropathy, a progressive kidney disease. Similarly,
hypertension can lead to hypertensive nephropathy, which affects the kidneys.
The high prevalence of diabetes and hypertension in Ireland directly translates
to a higher risk of kidney diseases among the population. Consequently, there
is an increased demand for kidney function tests to diagnose, monitor, and
manage kidney diseases associated with these conditions. According to
National Institute of Health, the prevalence of the four main categories of
chronic diseases among adults in Ireland has been estimated to be 9.4% for
asthma, 9.8% for Chronic obstructive pulmonary disease (COPD), 5.2% for
diabetes, and 4.3% for Cardiovascular (CVD). Diabetes, which affects in
excess of 250,000 people in Ireland is one of the leading causes of chronic
kidney disease. Diabetes check-ups should include the routine monitoring of
kidney function so that changes can be picked up early. It is easily done with
routine kidney blood and urine tests. Ireland is urging all people with
diabetes to attend for their routine diabetes checkups with their GP or
diabetes team, to ask for a kidney function test, and ensure that a discussion
of kidney health becomes an integral part of check-ups that helps to regulate
the growth of Ireland Kidney Function Test Market.
Download Free Sample Report
Government Initiatives and Schemes
The Irish government has
implemented various healthcare initiatives and policies to address the growing
burden of chronic diseases, including kidney-related conditions. These
initiatives aim to enhance early detection, improve patient outcomes, and
reduce healthcare costs. As a result, kidney function tests receive support and
attention, contributing to the growth of Ireland Kidney Function Test Market. Chronic
Kidney Disease (CKD) significantly increases the risk of negative outcomes in
people living with diabetes, cardiovascular disease and high blood pressure
amongst other health conditions. Therefore, the IKA’s campaign aims to
highlight that it is possible to prevent or slow down the progression of kidney
disease through lifestyle changes and medication and that it all starts with
simple blood and urine tests done by GP to measure and monitor kidney health.
As per the tagging line provided by the Irish Government, the Irish Kidney
Association’s campaign is ‘We’re Counting on You’. This represents the
importance for the public to be proactive in managing their kidney health and
that they are being ‘counted on’ to get a simple blood test and urine test
which will reveal their kidney function ‘numbers’. These ‘numbers’ will
represent how well the kidneys are functioning in filtering blood and removing
waste from the body. If Chronic Kidney Disease (CKD) is detected early enough,
its progression, through the five stages of CKD, can be slowed down supporting
better patient outcomes.
Personalized Medicine and
Precision Diagnostics
The trend toward personalized
medicine, where treatment approaches are tailored to individual patients, also
impacts the kidney function test market. Advancements in genetic testing,
molecular diagnostics, and biomarker identification enable better risk assessment,
early detection, and targeted treatment strategies. The integration of
precision diagnostics in kidney function testing enhances its value and
relevance in personalized patient care. Personalized medicine and precision
diagnostics facilitate the early detection of kidney diseases or disorders. By
utilizing genomic testing, proteomic analysis, and other advanced diagnostic
tools, healthcare professionals can identify individuals who are at a higher
risk of developing kidney problems. Early detection enables timely
interventions and preventive measures to slow down the progression of kidney
diseases, potentially reducing the burden on the healthcare system and leading
to the growth of the Ireland Kidney Function Test Market.
Market Segmentation:
The Ireland Kidney Function Test
Market is segmented by type, component, end user, regional landscape, and
competitive landscape. Based on type, the market is further bifurcated into
urine tests and blood tests. For urine tests, the market is segmented into Urine
Protein Tests, Creatinine Clearance Tests, and Microalbumin Tests. Based on blood
tests, the market is bifurcated into Serum Creatinine Tests, Glomerular
Filtration Rate Tests, and Blood Urea Nitrogen Tests. Based on the component,
the market is segmented into Dipsticks, Reagents, Kits & Assays, and
Others. Based on the end user, the market is segmented into Hospitals &
Clinics, Diagnostic Laboratories, and Others.
Market Players
Baxter Healthcare Limited, Abbott
Ireland Limited, Sysmex Ireland, Hoffmann-La Roche Ireland Limited, Danahar
Corporation Ireland Limited, Nova Biomedical Ireland Limited, Siemens
Healthineers Ireland, Arkray Ireland Limited, Fresenius Kabi Ireland, Randox
Laboratories Ltd etc. are some of the leading companies operating in the Ireland
Kidney Function Test Market.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historical Years
|
2018 – 2021
|
|
Estimated Year
|
2023E
|
|
Forecast Period
|
2024F – 2028F
|
|
Quantitative Units
|
Revenue in USD Million, CAGR for 2018-2022 and 2023E-2028F
|
|
Report Coverage
|
Revenue forecast, company share, competitive landscape, growth
factors, and trends
|
|
Segments Covered
|
Type
Component
End User
Region
Company
|
|
Region Scope
|
Northern Ireland, North-West, West, Midland East, Dublin, Shannon,
South-East, Cork-Kerry
|
|
Key Companies Profiled
|
Baxter Healthcare Limited, Abbott Ireland Limited, Sysmex
Ireland, Hoffmann-La Roche Ireland Limited, Danahar Corporation Ireland
Limited, Nova Biomedical Ireland Limited, Siemens Healthineers Ireland,
Arkray Ireland Limited, Fresenius Kabi Ireland, Randox Laboratories Ltd
|
|
Customization Scope
|
10% free report customization with purchase. Addition or
alteration to regional & segment scope.
|
|
Pricing and Purchase Options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase
options
|
|
Delivery Format
|
PDF and Excel through Email
(We can also provide the editable version of the report in PPT/Word format on
special request)
|
Report
Scope:
In this
report, Ireland Kidney Function Test Market has been segmented into
following categories, in addition to the industry trends which have also been
detailed below:
- Ireland Kidney Function Test Market, By Type:
o Urine Tests
o Blood Tests
- Ireland Kidney Function Test Market, By Urine
Tests:
o Urine Protein Tests
o Creatinine Clearance Tests
o Microalbumin Tests
- Ireland Kidney Function Test Market, By Blood
Tests:
o Serum Creatinine Tests
o Glomerular Filtration Rate Tests
o Blood Urea Nitrogen Tests
- Ireland Kidney Function Test Market, By
Component:
- Dipsticks
- Reagents
- Kits & Assays
- Others
- Ireland Kidney Function Test Market, By End
User:
- Hospitals &
Clinics
- Diagnostic
Laboratories
- Others
- Ireland Kidney Function Test Market, By
Region:
- Northern Ireland
- North-West
- West
- Midland East
- Dublin
- Shannon
- South-East
- Cork-Kerry
Competitive
Landscape
Company
Profiles: Detailed
analysis of the major companies present in Ireland Kidney Function Test Market.
Available
Customizations:
With the
given market data, TechSci Research offers customizations according to a
company’s specific needs. The following customization options are available for
the report:
Company
Information
Detailed analysis and profiling of additional
market players (up to five).
It is an
upcoming report to be released soon. If you wish an early delivery of this
report or want to confirm the date of release, please contact us at [email protected]